FDA fast tracks drugs for Ebola and Marburg viruses

News
Article

FDA has granted fast-track designation for the development of AVI-7288 and AVI-7537 (Sarepta Therapeutics), for the treatment of Marburg virus and Ebola virus, respectively.

FDA has granted fast-track designation for the development of AVI-7288 and AVI-7537 (Marburg hemorrhagic fever is a severe and potentially fatal disease in humans first recognized in 1967. It is caused by an RNA virus of the Filoviridae family and is understood to be endemic to Africa. The Marburg virus is classified as a Category A bioterrorism agent by the CDC, and was determined to pose a material threat to national security and public health by the Secretary of Homeland Security in 2006. Onset of the disease is often sudden, and the symptoms include fever, chills, nausea, vomiting, chest pain, and diarrhea. Increasingly severe symptoms may also include massive hemorrhaging and multiple organ dysfunctions. There are currently no treatments for Marburg virus infection beyond supportive care.The hemorrhagic fever caused by the Ebola virus is severe and often fatal in humans. The disease was first recognized in 1976 and is one of 2 members of a family of RNA viruses called Filoviridae. The disease is generally understood to be endemic to parts of Africa. Onset of illness from Ebola virus is abrupt with symptoms that include fever, headache, muscle ache, vomiting, and stomach pain. Internal and external bleeding may also be observed in some patients. There are currently no treatments for Ebola virus infection beyond supportive care and the mortality rate is very high.

Recent Videos
Related Content
MdBabul-stock.adobe.com

FDA Approves Second Biosimilar of Soliris

Formulary Watch
July 22nd 2024
Article

Epysqli is a monoclonal antibody that is approved to treat two rare conditions that break down red blood cells.

Read More

GoodRx to Offer Boehringer Ingelheim’s Humira Biosimilar

GoodRx to Offer Boehringer Ingelheim’s Humira Biosimilar

Formulary Watch
July 18th 2024
Article

Boehringer Ingelheim’s high- and low-concentration adalimumab-adbm will be available through GoodRx for $550 for two-pack, which represents a 92% discount from the Humira list price.

Read More

FDA Sets Review Date for Cell Therapy for Post-Transplant Complication

FDA Sets Review Date for Cell Therapy for Post-Transplant Complication

Formulary Watch
July 17th 2024
Article

If approved, tabelecleucel would be the first therapy specifically to treat Epstein-Barr virus related post-transplant lymphoproliferative disease. The FDA’s action date is Jan. 15, 2025.

Read More

FDA Issues Complete Response for High-Dose Opioid Rescue Med

FDA Issues Complete Response for High-Dose Opioid Rescue Med

Formulary Watch
July 16th 2024
Article

OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.

Read More

Increased Use of GLP-1 Drugs Adds to Navitus’ Drug Spend for 2023

Increased Use of GLP-1 Drugs Adds to Navitus’ Drug Spend for 2023

Denise Myshko
July 15th 2024
Article

The switch to biosimilars helped Navitus clients offset increased utilization in the non-specialty category and the introduction of higher-cost specialty drugs.

Read More

Yurii Kibalnik-stock.adobe.com

AbbVie Submits Applications for Rinvoq for Giant Cell Arteritis

Formulary Watch
July 12th 2024
Article

Giant cell arteritis is an inflammatory disease that affects the large blood vessels that supply blood to the head and brain.

Read More

© 2024 MJH Life Sciences

All rights reserved.